PA

sponsor

Your Unread Messages

Hello, Mary O'connor
Manage E-mail  |  Logout
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Guttman C – PCA3 molecular urine assay is a new tool for prostate cancer diagnosis that offers greater specificity than serum PSA. Data showed that combining PCA3 with free PSA and other risk factors significantly improves the accuracy for predicting biopsy outcome.

Related Articles

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09    Relevance Score: 72%

Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09    Relevance Score: 71%

A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09    Relevance Score: 71%

Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09    Relevance Score: 71%

Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09    Relevance Score: 71%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address